Hearing News Watch

LA JOLLA, CALIFORNIA — Scientists from the Salk Institute and the University of Sheffield co-led a study that shows promise for the development of gene therapies to repair hearing loss. In developed countries, roughly 80 percent of deafness cases that occur before a child learns to speak are due to genetic factors. One of these genetic components leads to the

SOMERSET, NEW JERSEY — Oticon, Inc. today announced the appointment of Jacob Winter as Vice President of Marketing. In his new role, Winter will lead Oticon’s product strategy, digital strategy and communication and campaign strategy. He joins Oticon, Inc. from Demant headquarters in Denmark, where he served as Director, Commercial Operations. Winter brings more than 10 years of marketing and

BUFFALO, NEW YORK – New University at Buffalo-led research shows how earbuds may soon be able to detect common ear infections and other ailments. A study published in June by the Association for Computing Machinery (ACM) describes what the research team is calling EarHealth. The system pairs Bluetooth earbuds with a smartphone that’s equipped with a deep learning platform. (Deep learning is

EDEN PRAIRIE, MINNESOTA – Starkey is proud to serve as the exclusive global supplier of hearing instruments for the Special Olympics Healthy Athletes® Healthy Hearing program at the 2022 Special Olympics Unified Cup, presented by Toyota and modelled after the FIFA World Cup™. The competition, which began July 31 and runs through August 6, is being held in Detroit, Michigan, and welcomes over

LYNGE, DENMARK — Realigning its organizational structure to better serve existing Hearing Care Professionals (HCPs) and their patients in the United States and Canada, while accelerating its development of Latin American business opportunities, WS Audiology today announced the formation of WSA Americas and appointed medical device and WSA veteran Carsten Buhl to serve as President of the new regional business

VANCOUVER, WASHINGTON — In a deal underlining the increasing importance of scalable,  digital processes for clinics in the multibillion-dollar allergy space, Audigy Group LLC has sold its comprehensive allergy-management platform, Clarity™, to Xtract Solutions.   The sale, which closed this week, further expands Xtract’s line of cloud-based immunotherapy software and allows Audigy to focus on its core business of audiology and

SAN DIEGO, CALIFORNIA — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all timepoints. The randomized, double-blind, placebo-controlled Phase 2 trial enrolled 153 patients with persistent, unilateral tinnitus of

SOMERSET, NEW JERSEY – The 2022 Oticon Audiology Summer Camp brought graduate students representing 21 US universities to Orlando, Florida for a 4-day series of lectures and workshops focused on preparing them for success as new professionals in the field of audiology. Launched in 1997, the annual professional development event is designed to supplement and complement students’ education with relevant,

CAMBRIDGE & TOKYO — Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc., a leader in regenerative medicine, have announced that the companies have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s proprietary direct cellular reprogramming platform, the collaboration

SEATTLE, WASHINGTON — Sound Pharmaceuticals has announced that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase 3 trial of an investigational new drug for the treatment of Meniere’s Disease (MD). Prior to STOPMD-3, all US based MD trials involved drugs that